Home/Filings/4/0001562180-23-001082
4//SEC Filing

Robichaud Albert 4

Accession 0001562180-23-001082

CIK 0001597553other

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 4:11 PM ET

Size

8.9 KB

Accession

0001562180-23-001082

Insider Transaction Report

Form 4
Period: 2023-02-03
Robichaud Albert
Chief Scientific Officer
Transactions
  • Award

    Common Stock

    2023-02-03+3,375146,680 total
  • Tax Payment

    Common Stock

    2023-02-03$44.16/sh1,127$49,768145,553 total
Footnotes (2)
  • [F1]On February 10, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 11,250 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 3,375 shares.
  • [F2]Reflects beneficial ownership balance which includes 279 shares purchased on June 30, 2022 and 397 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.

Issuer

Sage Therapeutics, Inc.

CIK 0001597553

Entity typeother

Related Parties

1
  • filerCIK 0001612861

Filing Metadata

Form type
4
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:11 PM ET
Size
8.9 KB